Clinical relevance of circulating cell-free microRNAs in cancer

Nature Reviews Clinical Oncology

Volumn 11, Issue 3, 2014, Pages 145-156

  Schwarzenbach, Heidi ^a   Nishida, Naohiro ^b   Calin, George A ^b   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE MICRORNA; MICRORNA; UNCLASSIFIED DRUG;

BODY FLUID; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RESISTANCE; DIGESTIVE SYSTEM CANCER; EARLY DIAGNOSIS; GYNECOLOGIC CANCER; HUMAN; LUNG CANCER; MICROARRAY ANALYSIS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; RNA EXTRACTION; RNA STABILITY; SEQUENCE ANALYSIS; TREATMENT RESPONSE;

HUMANS; MICRORNAS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84896703318     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.5     Document Type: Review

References (132)

1. Pritchard, C. C., Cheng, H. H. & Tewari, M. MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13, 358-369 (2012).
2. Cortez, M. A. et al. MicroRNAs in body fluids - the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8, 467-477 (2011).
3. Turchinovich, A., Weiz, L. & Burwinkel, B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem. Sci. 37, 460-465 (2012).
4. Kim, V. N. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol. Cell Biol. 6, 376-385 (2005). (Pubitemid 40637855)
5. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597-610 (2010).
6. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
7. Höck, J. & Meister, G. The Argonaute protein family. Genome Biol. 9, 210 (2008).
8. Portnoy, V., Huang, V., Place, R. F. & Li, L. C. Small RNA and transcriptional upregulation. Wiley Interdiscip. Rev. RNA 2, 748-760 (2011).
9. Place, R. F., Li, L. C., Pookot, D., Noonan, E. J. & Dahiya, R. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc. Natl Acad. Sci. USA 105, 1608-1613 (2008). (Pubitemid 351346562)
10. Vasudevan, S., Tong, Y. & Steitz, J. A. Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 1931-1934 (2007).
11. Suzuki, H. I. & Miyazono, K. Emerging complexity of microRNA generation cascades. J. Biochem. 149, 15-25 (2011).
12. Suzuki, H. I. et al. MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation. Mol. Cell 44, 424-436 (2011).
13. Esquela-Kerscher, A. & Slack, F. J. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).
14. Heneghan, H. M., Miller, N., Lowery, A. J., Sweeney, K. J. & Kerin, M. J. MicroRNAs as novel biomarkers for breast cancer. J. Oncol. 2009, 950201 (2009).
15. Stroun, M., Lyautey, J., Lederrey, C., Olson-Sand, A. & Anker, P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin. Chim. Acta 313, 139-142 (2001). (Pubitemid 33016703)
16. Okada, H., Kohanbash, G. & Lotze, M. T. MicroRNAs in immune regulation - opportunities for cancer immunotherapy. Int. J. Biochem. Cell Biol. 42, 1256-1261 (2010).
17. Ha, T. Y. The role of microRNAs in regulatory T cells and in the immune response. Immune Netw. 11, 11-41 (2011).
18. Toffanin, S., Sia, D. & Villanueva, A. microRNAs: new ways to block tumor angiogenesis? J. Hepatol. 57, 490-491 (2012).
19. Pegtel, D. M. et al. Functional delivery of viral miRNAs via exosomes. Proc. Natl Acad. Sci. USA 107, 6328-6333 (2010).
20. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654-659 (2007). (Pubitemid 47214727)
21. Vickers, K. C. & Remaley, A. T. Lipid-based carriers of microRNAs and intercellular communication. Curr. Opin. Lipidol. 23, 91-97 (2012).
22. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470-1476 (2008).
23. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005). (Pubitemid 40839735)
24. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl Acad. Sci. USA 103, 2257-2261 (2006). (Pubitemid 43271657)
25. Yu, S. L. et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13, 48-57 (2008).
26. Dvinge, H. et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 497, 378-382 (2013).
27. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
28. Arroyo, J. D. et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl Acad. Sci. USA 108, 5003-5008 (2011).
29. Kroh, E. M., Parkin, R. K., Mitchell, P. S. & Tewari, M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 50, 298-301 (2010).
30. Turchinovich, A., Weiz, L., Langheinz, A. & Burwinkel, B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 39, 7223-7233 (2011).
31. Pritchard, C. C. et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila.) 5, 492-497 (2012).
32. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, e179 (2005).
33. Ell, B. et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell 24, 542-556 (2013).
34. Dong, H. et al. MicroRNA: function, detection, and bioanalysis. Chem. Rev. (2013).
35. Castoldi, M. et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA 12, 913-920 (2006).
36. Shendure, J. & Ji, H. Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
37. Ryan, B. M., Robles, A. I. & Harris, C. C. Genetic variation in microRNA networks: the implications for cancer research. Nat. Rev. Cancer 10, 389-402 (2010).
38. Chang, H. T. et al. Comprehensive analysis of microRNAs in breast cancer. BMC Genomics 13 (Suppl. 7), S18 (2012).
39. Li, S. C. et al. miRNA arm selection and isomiR distribution in gastric cancer. BMC Genomics 13 (Suppl. 1), S13 (2012).
40. Williams, Z. et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc. Natl Acad. Sci. USA 110, 4255-4260 (2013).
41. Hafner, M. et al. RNA-ligase-dependent biases in miRNA representation in deep-sequenced small RNA cDNA libraries. RNA 17, 1697-1712 (2011).
42. Lawrie, C. H. et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 141, 672-675 (2008). (Pubitemid 351667616)
43. Shen, J. et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. BMC Cancer 11, 374 (2011).
44. Roth, C., Kasimir-Bauer, S., Pantel, K. & Schwarzenbach, H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol. Oncol. 5, 281-291 (2011).
45. Roth, C. et al. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS ONE 7, e38248 (2012).
46. Cui, E. H. et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol. Sin. 34, 309-313 (2013).
47. Wang, Y. et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 73, 4801-4809 (2013).
48. Hu, Z. et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J. Clin. Oncol. 28, 1721-1726 (2010).
49. Yuxia, M., Zhennan, T. & Wei, Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J. Cancer Res. Clin. Oncol. 138, 2045-2050 (2012).
50. Huang, Y. et al. MicroRNA-21 gene and cancer. Med. Oncol. 30, 376 (2013).
51. Liu, X. G. et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med. Oncol. 29, 618-626 (2012).
52. Sanfiorenzo, C. et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. PLoS ONE 8, e54596 (2013).
53. Pepek, J. M. et al. How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: a comparison of the TNM 6 and 7 systems. J. Thorac. Oncol. 6, 757-761 (2011).
54. Kaduthanam, S. et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80, 223-227 (2013).
55. Silva, J. et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur. Respir. J. 37, 617-623 (2011).
56. Wang, T. et al. Cell-free microRNA expression profiles in malignant effusion associated with patient survival in non-small cell lung cancer. PLoS ONE 7, e43268 (2012).
57. Chen, W., Cai, F., Zhang, B., Barekati, Z. & Zhong, X. Y. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 34, 455-462 (2013).
58. Eichelser, C., Flesch-Janys, D., Chang-Claude, J., Pantel, K. & Schwarzenbach, H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin. Chem. 59, 1489-1496 (2013).
59. Wang, F., Zheng, Z., Guo, J. & Ding, X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol. Oncol. 119, 586-593 (2010).
60. Roth, C. et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 12, R90 (2010).
61. Schwarzenbach, H., Milde-Langosch, K., Steinbach, B., Muller, V. & Pantel, K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res. Treat. 134, 933-941 (2012).
62. Asaga, S. et al. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem. 57, 84-91 (2011).
63. Schwarzenbach, H., Hoon, D. S. & Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer 11, 426-437 (2011).
64. Gorges, T. M. & Pantel, K. Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol. Immunother. 62, 931-939 (2013).
65. Kang, Y. & Pantel, K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 23, 573-581 (2013).
66. Zhang, L. et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin. Cancer Res. 18, 5701-5710 (2012).
67. Madhavan, D. et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin. Cancer Res. 18, 5972-5982 (2012).
68. Roth, C., Kasimir-Bauer, S., Heubner, M., Pantel, K. & Schwarzenbach, H. in Circulating nucleic acids in plasma and serum (ed. Gahan, P. B.) 63-71 (Springer, 2011).
69. Hong, F., Li, Y., Xu, Y. & Zhu, L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. J. Int. Med. Res. 41, 64-71 (2013).
70. Xu, Y. Z., Xi, Q. H., Ge, W. L. & Zhang, X. Q. Identification of serum MicroRNA-21 as a biomarker for early detection and prognosis in human epithelial ovarian cancer. Asian Pac. J. Cancer Prev. 14, 1057-1060 (2013).
71. Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 138, 671-674 (2012).
72. Chen, J. et al. Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int. J. Mol. Med. 32, 557-567 (2013).
73. Zhao, S., Yao, D., Chen, J. & Ding, N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet. Test. Mol. Biomarkers 17, 631-636 (2013).
74. Yaman Agaoglu, F. et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 32, 583-588 (2011).
75. Nguyen, H. C. et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73, 346-354 (2012).
76. Zhang, H. L. et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71, 326-331 (2011).
77. Shen, J. et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72, 1469-1477 (2012).
78. Brase, J. C. et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int. J. Cancer 128, 608-616 (2011).
79. Selth, L. A. et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br. J. Cancer 109, 641-650 (2013).
80. Bryant, R. J. et al. Changes in circulating microRNA levels associated with prostate cancer. Br. J. Cancer 106, 768-774 (2012).
81. Shah, M. A. & Kurtz, R. C. Upper gastrointestinal cancer predisposition syndromes. Hematol. Oncol. Clin. North Am. 24, 815-835 (2010).
82. Han, M. et al. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol. Cell Biochem. 363, 427-436 (2012).
83. Komatsu, S. et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 105, 104-111 (2011).
84. Takeshita, N. et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br. J. Cancer 108, 644-652 (2013).
85. Liu, R. et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. J. Toxicol. Environ. Health A 75, 1154-1162 (2012).
86. Cheng, H. et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS ONE 6, e17745 (2011).
87. Wang, L. G. & Gu, J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 36, e61-e67 (2012).
88. Kuo, T. Y. et al. Computational analysis of mRNA expression profiles identifies microRNA-29a/c as predictor of colorectal cancer early recurrence. PLoS ONE 7, e31587 (2012).
89. Ng, E. K. et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58, 1375-1381 (2009).
90. Tsai, K. W. et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer 51, 394-401 (2012).
91. Valladares-Ayerbes, M. et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J. Transl. Med. 10, 186 (2012).
92. Komatsu, S. et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 33, 271-276 (2013).
93. Zhou, H. et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl.) 88, 709-717 (2010).
94. Yamamoto, Y. et al. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 14, 529-538 (2009).
95. Zhou, J. et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 29, 4781-4788 (2011).
96. Koberle, V. et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur. J. Cancer 49, 3442-3449 (2013).
97. Tomimaru, Y. et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 56, 167-175 (2012).
98. Liu, J. et al. Combination of plasma microRNAs with serum CA19-19 for early detection of pancreatic cancer. Int. J. Cancer 131, 683-691 (2012).
99. Liu, R. et al. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 58, 610-618 (2012).
100. Hanash, S. M., Baik, C. S. & Kallioniemi, O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142-150 (2011).
101. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 3, e3148 (2008).
102. Chim, S. S. et al. Detection and characterization of placental microRNAs in maternal plasma. Clin. Chem. 54, 482-490 (2008). (Pubitemid 351348154)
103. Le, H. B. et al. Evaluation of dynamic change of serum miR-21 and miR-24 in pre- and post-operative lung carcinoma patients. Med. Oncol. 29, 3190-3197 (2012).
104. Jung, E. J. et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118, 2603-2614 (2012).
105. Zheng, D. et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int. J. Clin. Exp. Pathol. 4, 575-586 (2011).
106. Sun, Y. et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE 7, e47003 (2012).
107. Ohyashiki, K. et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. PLoS ONE 6, e16408 (2011).
108. Wei, J. et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin. J. Cancer 30, 407-414 (2011).
109. Kurashige, J. et al. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J. Surg. Oncol. 106, 188-192 (2012).
110. Wang, P. et al. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol. Oncol. 7, 334-345 (2013).
111. Zhou, M. et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem. 285, 21496-21507 (2010).
112. Wang, H. et al. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS ONE 7, e34210 (2012).
113. Lee, L. W. et al. Complexity of the microRNA repertoire revealed by next-generation sequencing. RNA 16, 2170-2180 (2010).
114. Madhavan, D., Cuk, K., Burwinkel, B. & Yang, R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front. Genet. 4, 116 (2013).
115. Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775-789 (2010).
116. Janssen, H. L. et al. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 368, 1685-1694 (2013).
117. Kalluri, R. & Zeisberg, M. Fibroblasts in cancer. Nat. Rev. Cancer 6, 392-401 (2006).
118. Fabbri, M. et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc. Natl Acad. Sci. USA 109, E2110-E2116 (2012).
119. Chen, X. et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int. J. Cancer 130, 1620-1628 (2012).
120. Yu, J. et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 138, 671-674 (2012).
121. Redova, M. et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 10, 55 (2012).
122. Wang, S. et al. A plasma microRNA panel for early detection of colorectal cancer. Int. J. Cancer http://dx.doi.org/10.1002/ijc.28136 (2013).
123. Liu, R. et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47, 784-791 (2011).
124. Zhang, C. et al. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin. Chem. 56, 1871-1879 (2010).
125. Hsu, C. M. et al. Circulating miRNA is a novel marker for head and neck squamous cell carcinoma. Tumour Biol. 33, 1933-1942 (2012).
126. Yu, S. et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 97, 2084-2092 (2012).
127. Yang, C. et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int. J. Cancer 132, 116-127 (2013).
128. Kanemaru, H. et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J. Dermatol. Sci. 61, 187-193 (2011).
129. Zuo, Z. et al. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood 118, 413-415 (2011).
130. Guo, H. Q., Huang, G. L., Guo, C. C., Pu, X. X. & Lin, T. Y. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. Dis. Markers 29, 251-258 (2010).
131. Ferrajoli, A. et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemia. Blood 122, 1891-1899 (2013).
132. Tanaka, K. et al. Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal Cancer. Ann. Surg. Oncol. 20 (Suppl. 3), 670-615 (2013).